Genetic Testing for Prostate Cancer in Clinical Practice

Main|Search|PHGKB




Last Posted: Jul 01, 2017

---

• Genetic Testing for Prostate Cancer in Clinical Practice  
  CC Pritchard, JCO Precision Oncology, June 2017
• Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.  
  Mühlberger Nikolai et al. BMC public health 2017 Jun 17(1) 596
• Should I Get Screened for Prostate Cancer? 
• Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer  
  NCI, June 9, 2017
• Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS).  
  Ferro Matteo et al. International journal of molecular sciences 2017 May 18(6)
• New blood test uses nanotechnology to predict aggressive prostate cancer accurately  
  Science Mag, June 9, 2017
• Genetics of Prostate Cancer (PDQ®) -Health Professional Version  
  PDQ Cancer Genetics Editorial Board, NCI, May 2017
• Genetics of Prostate Cancer (PDQ®) -Health Professional Version  
  PDQ Cancer Genetics Editorial Board, NCI, May 2017
• Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.  
  Nguyen Paul L et al. European urology 2017 May
• Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system.  
  Voigt Jeffrey D et al. Reviews in urology 2017 19(1) 1-10
• Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.  
  Conteduca V et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 May
• Thousands of men with prostate cancer get risky treatment they don’t need. New approaches could curb that  
  S Begley, StatNews, May 4, 2017
• Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study —Π 
  V. Conteduca, et al. Ann Oncology, May 2017
• Decision making tools in prostate cancer: from risk grouping to nomograms.  
  Fontanella Paolo et al. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2017 Mar
• Prognostic outlier genes for enhanced prostate cancer treatment.  
  Kim Hyun et al. Future oncology (London, England) 2017 Feb 13(3) 249-261
• Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.  
  Alvarez-Cubero M J et al. Molecular diagnosis & therapy 2017 Apr 21(2) 167-178

more